ALS Center of Excellence hires managing director, forms inaugural board of directors

September 14, 2018  //  FOUND IN: News

Dennis Michael Ritter, M.D., has been hired as the managing director of the U-M ALS Center of Excellence. Additionally, the center has assembled a 13-member board of directors, comprised of business and community leaders.

As managing director, Ritter has oversight of the strategic direction of the center and its newly-formed board. He will provide leadership and professional expertise on matters related to the management of the center. Ritter will collaborate with the board to foster public awareness of ALS, expand marketing efforts through written and visual materials, and assist with the fulfillment of fundraising goals.

“Given Dr. Ritter’s experience in a variety of hospital committees and clinic management at Mercy Medical Center in St. Louis, he will bring the ALS Center’s level of operation to new heights,” said Eva Feldman, M.D., Ph.D., research director for the center, director of the Program for Neurology Research & Discovery and the Russell N. DeJong Professor of Neurology. “He also has a deep appreciation for patient care as a result of his outstanding career in medicine.”

“I could not be more proud to join the world-class ALS Center of Excellence team at Michigan Medicine,” said Ritter. “My longstanding experience as medical director of a large clinic in St. Louis will give me the tools to honor and assist our ALS patients and their caregivers, to achieve the goals of our Board, and to support the outstanding contributions to ALS research and clinical care by our physicians, Dr. Eva Feldman, Dr. Stephen Goutman and Dr. Dustin Nowacek.”

The board will support the Center’s mission of conducting basic science and clinical research, and providing exceptional clinical care to amyotrophic lateral sclerosis (ALS) patients and their caregivers. Board members are also charged with improving public knowledge about ALS and how it is treated.

“ALS is a disease that we must defeat and not be defeated by,” said Feldman. “It is a disease that requires more attention from the scientific community, as well as the general public. I am thrilled to welcome these public leaders to our board, many of whom have been personally touched by ALS.”

For a look at all who make up the inaugural 2018 board of directors, click here.